Crescita Therapeutics Stock Probability of Future Pink Sheet Price Finishing Over 72.79
| CRRTF Stock | USD 0.45 0.00 0.00% |
Crescita |
Crescita Therapeutics Target Price Odds to finish over 72.79
The tendency of Crescita Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 72.79 or more in 90 days |
| 0.45 | 90 days | 72.79 | close to zero percent |
Based on a normal probability distribution, the odds of Crescita Therapeutics to move over $ 72.79 or more in 90 days from now is close to zero percent (This Crescita Therapeutics probability density function shows the probability of Crescita Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Crescita Therapeutics price to stay between its current price of $ 0.45 and $ 72.79 at the end of the 90-day period is about 20.91 .
Assuming the 90 days horizon Crescita Therapeutics has a beta of -29.73 suggesting as returns on its benchmark rise, returns on holding Crescita Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Crescita Therapeutics is expected to outperform its benchmark. In addition to that Crescita Therapeutics has an alpha of 35.1627, implying that it can generate a 35.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Crescita Therapeutics Price Density |
| Price |
Predictive Modules for Crescita Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Crescita Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Crescita Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Crescita Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Crescita Therapeutics is not an exception. The market had few large corrections towards the Crescita Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Crescita Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Crescita Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 35.16 | |
β | Beta against Dow Jones | -29.73 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | 0.12 |
Crescita Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Crescita Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Crescita Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Crescita Therapeutics is way too risky over 90 days horizon | |
| Crescita Therapeutics has some characteristics of a very speculative penny stock | |
| Crescita Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 16.77 M. Net Loss for the year was (1.1 M) with profit before overhead, payroll, taxes, and interest of 10.01 M. | |
| Crescita Therapeutics has accumulated about 10.5 M in cash with (1.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3 |
Crescita Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Crescita Pink Sheet often depends not only on the future outlook of the current and potential Crescita Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Crescita Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21 M |
Crescita Therapeutics Technical Analysis
Crescita Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Crescita Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Crescita Therapeutics. In general, you should focus on analyzing Crescita Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Crescita Therapeutics Predictive Forecast Models
Crescita Therapeutics' time-series forecasting models is one of many Crescita Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Crescita Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Crescita Therapeutics
Checking the ongoing alerts about Crescita Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Crescita Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Crescita Therapeutics is way too risky over 90 days horizon | |
| Crescita Therapeutics has some characteristics of a very speculative penny stock | |
| Crescita Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 16.77 M. Net Loss for the year was (1.1 M) with profit before overhead, payroll, taxes, and interest of 10.01 M. | |
| Crescita Therapeutics has accumulated about 10.5 M in cash with (1.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3 |
Other Information on Investing in Crescita Pink Sheet
Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.